Quantech prepares to launch cardiac test panel:
This article was originally published in Clinica
Quantech has submitted a 510(k) clearance application to the FDA for a test of the cardiac marker CK-MB. CK-MB is one of three human proteins that are considered to be definitive diagnostic markers for heart attack. The others are myoglobin - for which the company already sells a test - and troponin I. St Paul, Minnesota-based Quantech plans to launch a cardiac test panel for all three proteins for its DBx rapid diagnostic system. The system consists of a table-top instrument and disposable biosensers that use the company's Surface Plasmon Resonance (SPR) technology.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.